Posted by Michael Wonder on 20 Dec 2021
Biogen cuts price for Alzheimer’s drug Aduhelm by half
20 December 2021 - The drug has sold poorly since its approval in June due to concerns about its safety, effectiveness and cost.
The price cut will reduce the average annual cost of treatment to $28,200 a patient from the $56,000 the company set when the drug was approved in June, Biogen said Monday.
